Meeting
2011 ASCO Annual Meeting
A population-based study of glioblastoma multiforme (GBM) in the new stupp paradigm: Have we improved outcome?
Authors
Z. Lwin
Princess Margaret Hospital, Toronto, ON, Canada
Z. Lwin , D. MacFadden , A. AL-Zahrani , E. Atenafu , B. Miller , C. Menard , N. Laperriere , W. P. Mason
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 29: 2011 (suppl; abstr 2012)
Abstract #
2012
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Comparison of survival outcomes of patients with newly diagnosed glioblastoma treated with standard chemoradiation in and outside of clinical trials.
First Author: Rifaquat Rahman
Poster
2022 ASCO Annual Meeting
Clinical application of a functional 3D ex vivo test to predict therapeutic response in patients with HGG: A progression-free survival analysis.
First Author: Lindsay J Lipinski
Poster
2019 ASCO Annual Meeting
Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).
First Author: Hao-Wen Sim
Poster
2018 ASCO Annual Meeting
Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma.
First Author: Howard Colman